ALNY Q1 2019 Earnings — Alnylam Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ALNYAlnylam Pharmaceuticals, Inc.

$42B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$33M+52.0% YoY

Gross Profit

$30M89.9% margin

Operating Income

-$189M-567.0% margin

Net Income

-$182M-546.4% margin

EPS (Diluted)

$-1.73

QoQ Revenue Growth

+58.3%

Cash Flow

Operating Cash Flow

-$189M

Free Cash Flow

-$233M

Stock-Based Comp.

$32M

Balance Sheet

Total Assets

$2.0B

Total Liabilities

$467M

Stockholders' Equity

$1.5B

Cash & Equivalents

$725M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$33M	$22M	+52.0%
Gross Profit	$30M	$22M	+36.8%
Operating Income	-$189M	-$147M	-28.1%
Net Income	-$182M	-$141M	-28.8%

Revenue Segments

Product

$26M100%